Emyria has released its half-yearly report for the period ending December 2022. Highlights include:

Advancement towards our Phase 3 Clinical Trial of EMD-RX5 (now underway);
Progress in novel MDMA-analogue drug discovery; and
Acceptance into selective National Institutes of Health Program

Read the report here: https://investorhub.emyria.com/4328204